Kodiak Sciences (KOD) is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic and high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate platform is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently marketed biologic medicines for treating retinal diseases. The company currently has no marketed drug in its portfolio. Kodiak is ...

A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD) . Shares have lost about 8.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Kodiak Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Kodiak Q2 Loss Narrower Than Expected ...

Kodiak Sciences Inc. (KOD) incurred a loss of 86 cents per share in the second quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 87 cents. The company had incurred a loss of $1.53 per share in the year-ago quarter. The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues. Quarter in Detail Research and development expenses were $32.5 million in the reported quarter, down 51.5% year over year. The decrease was mai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results Palo Alto, CA — August 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy ...

PALO ALTO, Calif., Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy continues to enroll. The Phase 3 DAYBREAK study of tarcocimab and KSI-501 is now actively enr ...

Kodiak Sciences Inc. (KOD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a chan ...

Toward the end of last year, Kodiak Sciences decided to reboot the development program of its lead candidate, tarcocimab (a novel anti-VEGF ABC), after witnessing positive top-line results from its phase III GLOW study evaluating the same in moderately severe to severe non-proliferative diabetic retinopathy (NPDR). Building on the success of the GLOW1 study, KOD initiated the pivotal phase III GLOW2 study evaluating tarcocimab in diabetic retinopathy, which is actively enrolling patients, during the fourth ...

It has been about a month since the last earnings report for Kodiak Sciences Inc. (KOD) . Shares have lost about 26.2% in that time frame, underperforming the S&P 500. Kodiak Q1 Loss Narrower Than Expected, Pipeline in Focus Currently, KOD does not have any approved products in its portfolio. As a result, it is yet to generate revenues. Research and development expenses were $29.9 million in the reported quarter, down 47% year over year. The decrease was mainly due to the reduction in expenses owing to the ...

Core Insights - Kodiak Sciences Inc. is focused on developing transformative therapeutics for retinal diseases and will present at several upcoming investor conferences [1][2][7] - The company is advancing a clinical pipeline that includes three product candidates, with two in late-stage development [3][4][5][6] Company Overview - Kodiak Sciences is a biopharmaceutical company dedicated to treating retinal diseases using its proprietary ABC Platform™, which integrates protein-based and chemistry-based therapies [3] - The company aims to address leading causes of blindness globally through innovative drug design and development [3] Clinical Pipeline - Kodiak's lead product, tarcocimab, is an anti-VEGF antibody biopolymer conjugate targeting diabetic retinopathy and wet age-related macular degeneration [4] - KSI-501, a bispecific antibody biopolymer conjugate, is designed to treat retinal vascular diseases by inhibiting IL-6 and VEGF pathways, with Phase 3 studies expected to begin mid-2024 [5] - KSI-101, an unconjugated protein candidate, is being developed for retinal inflammatory diseases, filling a gap in current treatment options [6] Upcoming Events - Kodiak will participate in the Clinical Trials at the Summit 2024 on June 8, where presentations on its clinical pipeline will be made [2] - The company will also present at the Jefferies Healthcare Conference on June 6 and the Goldman Sachs Global Healthcare Conference on June 13 [7][8]